JP6653253B2 - ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体 - Google Patents

ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体 Download PDF

Info

Publication number
JP6653253B2
JP6653253B2 JP2016526992A JP2016526992A JP6653253B2 JP 6653253 B2 JP6653253 B2 JP 6653253B2 JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016526992 A JP2016526992 A JP 2016526992A JP 6653253 B2 JP6653253 B2 JP 6653253B2
Authority
JP
Japan
Prior art keywords
group
amino
alkyl
optionally substituted
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016526992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529235A5 (https=
JP2016529235A (ja
Inventor
リチャード エル ベアード
リチャード エル ベアード
ティエン ティー ドゥオン
ティエン ティー ドゥオン
ジョン イー ドネッロ
ジョン イー ドネッロ
ヴィーナ ヴィスワナス
ヴィーナ ヴィスワナス
ガースト　マイケル　イー
マイケル イー ガースト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2016529235A publication Critical patent/JP2016529235A/ja
Publication of JP2016529235A5 publication Critical patent/JP2016529235A5/ja
Application granted granted Critical
Publication of JP6653253B2 publication Critical patent/JP6653253B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016526992A 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体 Expired - Fee Related JP6653253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846787P 2013-07-16 2013-07-16
US61/846,787 2013-07-16
PCT/US2014/046203 WO2015009545A1 (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Publications (3)

Publication Number Publication Date
JP2016529235A JP2016529235A (ja) 2016-09-23
JP2016529235A5 JP2016529235A5 (https=) 2017-08-17
JP6653253B2 true JP6653253B2 (ja) 2020-02-26

Family

ID=51230227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526992A Expired - Fee Related JP6653253B2 (ja) 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体

Country Status (11)

Country Link
US (1) US9428549B2 (https=)
EP (1) EP3022174B1 (https=)
JP (1) JP6653253B2 (https=)
KR (1) KR102313757B1 (https=)
CN (1) CN105377814B (https=)
AU (1) AU2014290618B2 (https=)
CA (1) CA2917811C (https=)
DK (1) DK3022174T3 (https=)
ES (1) ES2708571T3 (https=)
RU (1) RU2696581C2 (https=)
WO (1) WO2015009545A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518742B (zh) 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
BR112015021392B1 (pt) * 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
RU2703725C1 (ru) 2013-11-21 2019-10-22 Аллерган, Инк. Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
ES2752733T3 (es) 2013-11-28 2020-04-06 Kyorin Seiyaku Kk Derivados de urea deuterados o marcados isotópicamente o sales farmacológicamente aceptables de los mismos útiles como agonistas de FPRL-1
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
CA2948876A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
JP6746613B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CA2992662A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
HU219913B (hu) * 1994-02-09 2001-09-28 Shionogi And Co. Ltd. Karbamoilezett dipeptidszármazékok és ezeket tartalmazó gyógyszerkészítmények
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
WO1999065932A1 (en) 1998-06-18 1999-12-23 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
WO2003082314A2 (en) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
EP1692502A2 (en) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AU2010250789B2 (en) * 2009-05-18 2015-05-14 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists
WO2012074785A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CN106518742B (zh) * 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8735622B2 (en) * 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
BR112015021392B1 (pt) * 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
BR122017004254B1 (pt) * 2013-03-06 2021-04-13 Allergan, Inc. Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares

Also Published As

Publication number Publication date
AU2014290618B2 (en) 2018-04-05
DK3022174T3 (da) 2019-01-02
CN105377814A (zh) 2016-03-02
US9428549B2 (en) 2016-08-30
US20150025021A1 (en) 2015-01-22
KR20160031007A (ko) 2016-03-21
CA2917811A1 (en) 2015-01-22
RU2016104844A (ru) 2017-08-21
RU2696581C2 (ru) 2019-08-05
JP2016529235A (ja) 2016-09-23
AU2014290618A1 (en) 2016-02-18
ES2708571T3 (es) 2019-04-10
KR102313757B1 (ko) 2021-10-18
CN105377814B (zh) 2018-04-03
EP3022174A1 (en) 2016-05-25
EP3022174B1 (en) 2018-09-05
WO2015009545A1 (en) 2015-01-22
CA2917811C (en) 2021-08-31

Similar Documents

Publication Publication Date Title
JP6804580B2 (ja) ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体
JP6653253B2 (ja) ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
RU2627271C2 (ru) Производные арилмочевины в качестве модуляторов n-формилпептидного-1 рецептора (fprl-1)
JP6660889B2 (ja) ホルミルペプチド受容体調節物質としてのイミダゾール誘導体
WO2015042071A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
US9868700B2 (en) Carbamoyl hydrazine derivatives as formyl peptide modulators
HK1225012B (en) Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
HK1225012A1 (en) Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
HK1228885A (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1228885A1 (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1199622B (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200127

R150 Certificate of patent or registration of utility model

Ref document number: 6653253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees